William Blair

“Crossover investors and generalist asset managers are rotating out of over-indexed AI/tech positions and back into biopharma as a diversification play. The IPO window is reopening with conviction — deals are not just getting done, they're getting upsized.”

“There were more exits in Q1 than in any quarter since Q4 2021, at the tail end of the pandemic-era boom.”